A new study demonstrated that tumor-derived IgG, which is recognized by RP215, suppressed effector T-cell proliferation and promoted tumor growth by reducing CD4+ and CD8+ T-cell infiltration into tumor tissues. This evidence concerns the gene CD4 and neoplasm.